chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Projectile vomiting; Dry heaves; Vaccine arm was a little sore; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING PROJECTILE (Projectile vomiting), RETCHING (Dry heaves), VACCINATION SITE PAIN (Vaccine arm was a little sore) and NAUSEA (Nausea) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 005C21A and 020B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Jun-2021, the patient experienced VOMITING PROJECTILE (Projectile vomiting), RETCHING (Dry heaves), VACCINATION SITE PAIN (Vaccine arm was a little sore) and NAUSEA (Nausea). At the time of the report, VOMITING PROJECTILE (Projectile vomiting) and VACCINATION SITE PAIN (Vaccine arm was a little sore) outcome was unknown, RETCHING (Dry heaves) had resolved and NAUSEA (Nausea) had not resolved.            The action taken with mRNA-1273(Moderna COVID-19 vaccine) was not applicable  No concomitant medications were reported  No treatment drugs were reported
Second Dose given 2 days early. Psychiatric patient caused distraction and misread vaccine card 4/08 for 4/06, being 2 days too soon.
About 16 hours after the shot, she had a fever of 100.0, she felt very sick, nauseous, feverish, didn't eat breakfast like normal, didn't sleep last night as well. The fever broke and she's starting to feel better but it's making everyone concerned about the second shot.
Right arm deltoid area red; swollen; hot to the touch 17.5cm x 9cm.  Physical Exam by Dr. Rash: Pink, swollen around injection site (no drainage) noted.  Dx: Cellulitis Rx: Ibuprofen 100mg/5ml and Cefdinir 125mg/5ml.  Advised cold compresses; call office if symptoms worsen.
I had a bad headache, sore throat, body aches, chills, cough, and fatigue. I tested positive for COVID-19 at home. I talked my doctor, and they prescribed me PAXLOVID. I had a bad reaction to PAXLOVID, and I started itching everywhere. I stop taking after the 3 days. I still am dealing with fatigue and running nose.
SWOLLEN LYMPH NODES, NO FEVER, NO SOB, NO PAIN OR REDNESS.  NODES BECAME LARGER AND MORE NOTICEABLE THE NEXT DAY AND "JIGGLED WITH MOVEMENT" , NO OTHER SYMPTOMS APPEARED.  CLIENT WAS SEEN AT URGENT CARE AND TOLD TO CONTINUE MONITORING SYMPTOMS.
Patient had low level of consciousness, became diaphoretic and clammy. Ammonia inhalent used. Pt assisted to exam table after alert. Vital signs taken. Dr. also checked pt.  DX Vasovagal reaction.
Information has been received from a receptionist concerning her daughter who was vaccinated with a first dose of Gardasil.  Concomitant therapy included influenza virus vaccine (manufacturer unknown).  Subsequently on the same day the patient experienced achiness and fatigue.  Subsequently, by the next morning, she had fully recovered.  Additional information has been requested.
This is a spontaneous report from a contactable consumer or other non-health care professional (son). A male patient of an unspecified age received third dose of bnt162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 28Oct2021 (reported as yesterday) as dose 3 (booster), single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. Historical vaccine included, patient previously received second dose of bnt162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration, on an unspecified date as dose 2, single and also received first dose of bnt162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration, on an unspecified date as dose 1, single both for covid-19 immunization. Reporter stated my father had on 28Oct2021 (reported as yesterday) booster Pfizer and right now (captured as 29Oct2021), he has 100.7 temperature and he is little lethargic and his muscles are hurting. The patient underwent lab tests and procedures which included body temperature resulted as 100.7 fahrenheit on an unspecified date in 29Oct2021. Outcome of the events was unknown.Reporter type could not be probed as reporter hung up the call abruptly, hence reporter type captured as consumer or non-healthcare professional by default. The lot number for BNT162B2 was not provided and will be request during follow-up.
Injection site pain; Chills; Feeling unwell; Tiredness/ "I" threw up/ more tiredness; Nausea; Headache; "I" threw up; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Mar2021 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was allergic to CIPRO. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date as a single dose for COVID-19 immunisation. On 04Mar2021, the patient experienced chills, feeling unwell, tiredness, threw up, more tiredness, nausea and headache. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, feeling unwell, tiredness, threw up, more tiredness, nausea and headache were resolved on an unknown date in Mar2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
After the second shot, started feeling dizziness and sob with exertion. Also I am having to take deep breaths frequently throughout the day without exertion. Seen at my PCP office yesterday, told abnormal EKG, but echo can?t be completed until the end of next week.
Patient came in with his sister for his flu shot this fall. At that time his Mom mentioned that he had a mark from his HPV vaccine. After further examination he did have a raised red area 8 cm round. Patient denied any pain.
Slight sore throat and that is all I ever had. It lasted 10 days. I didn't take anything for it. I had a health visit with nurse at doctor's office. I took a COVID test August 24th  and it came back negative.
Pronounced fatigue in the morning, followed by 102 Fahrenheit fever, rapid breathing, shortness of breath, nausea, extreme pain in intestines/bowels (unable to sleep/rest), constant and severe (24/7) diarrhea, blood in stool mucus, headache.
Pain and local site of inject. Icing has not help. Recommend continue icing with ibuprofen. Patient also to contact vaccination 800 number.
7pm could not raise right arm.  Had severe headache & fatigue, chills and confusion ongoing, joint pain especially small joints. Have ongoing muscle pain, fatigue & confusion.
Case had arm pain the night of the vaccination. Case woke up the next morning with eye pain, blurry vision, headache, bodyaches and a fever of 103.2. Case states that this also happened with first dose. Case did call personal physician.
4 inch round area with swelling, redness, itching around injection site.  Began at 1300 on 2/3/2021 continues today.
Breakthrough case admission after 2 vaccines Pfizer 11/3/21 Lot# FD0810;  Pfizer 11/24/21 Lot# FJ8757
Immediately after receiving flu vaccine and covid booster began to c/o ringing in the ear and blurry vision. Writer provided water and graham crackers, was instructed to wait in the clinical area in recliner while reclined until symptoms subside. Will continue to monitor.
Skin rash (hives) on arms, back, and abdomen. Took two 25 mg tablets of Diphenhydramine hydrochloride at 9 PM. Skin rash persisted and itchiness subsided around 11 PM. At 6 AM on 10/05/2010, slight rash. Took one 25 mg tablets of Diphenhydramine hydrochloride at 7:20 AM. Have muscular-like soreness around injection site from the time of the vaccine to present (10/5/2010 @11:15 AM).
Had dizziness the next morning, and reduced sensory in left foot, and feeling of weakness.  Dizziness settled a bit but about 1.5 weeks later it came back with dizzy spells daily occurring throughout the day with head pressure, foggy feeling and a disconnected feeling also a feeling of weakness more in left leg but general feeling of weakness, as well as Nausea that comes and goes, also roaming headaches usually mild not severe.  Symptoms have continued on and off each day with some days more symptoms and some days less symptoms.
RN called to report that 31 year old patient requests 3rd dose of GARDASIL 9 after 2nd dose last received at 17 years old. No further information provided. No additional AEs, no PQCs.; This spontaneous report was received from a register nurse referring to a 31 year old female patient. No information regarding her pertinent medical history, concomitant therapy and drug reactions or allergies were provided.  On an unknown date, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 mil, once.  On unspecified date (when the patient was 17 years old), the patient was vaccinated with the second of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) 0.5 mil, once.  Currently, the patient requested the third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (31 years old) (inappropriate schedule of product administration).
Pfizer COVID-19 shot administered for the second dose; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Pfizer COVID-19 shot administered for the second dose) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939906) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Sep-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Pfizer COVID-19 shot administered for the second dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Pfizer COVID-19 shot administered for the second dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
More than six months since first dose; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in 16th July 2019 by Intramuscular route, which was more than six months from the date of reporting).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional case details were reported as follows: The case was reported by patient. The age at vaccination was not applicable for this report. The patient did not received 2nd dose till the time of reporting which led to incomplete course of vaccination. The patient asked to find out if she needs to restart the Shingrix series since it's been more than six months since her first dose. The patient stated she plans on getting the 2nd dose in the near future after speaking to her health care professional.  The reporter consented to follow up.
I started having a headache and some archness the next day. I thought it was pretty normal. That day I did receive the Flu vaccine that same day. It lasted no more than 24 hours.I tested at home called my doctor he gave Paxlovid. I took the medication, and it did help for one day I was okay and then my health went back downhill again.   Last Monday I did send another note to my doctor and the doctor did a chest X-Ray and it came back clear but I was told to rest but I am still very congestion.
11cm x 12cm swelling/redness at shot site. Mom applied ice intermittently. No SOB, some tenderness and itching. Reaction appears localized. In office told to take oral BENADRYL and topical hydrocortisone BID PRN reaction was noticed 72 hrs after immunization.
I have ME/CFS/ my condition has been exacerbated; I have ME/CFS/ my condition has been exacerbated; I have ME/CFS/ my condition has been exacerbated; normal soreness around injection site for a few days; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date May2021 (Batch/Lot number: unknown) at the age of 68 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "ME/CFS" (unspecified if ongoing), notes: ME/CFS; "ME/CFS" (unspecified if ongoing), notes: ME/CFS; "Reactivated Epstein-Barr", start date: 2020 (unspecified if ongoing), notes: reactivated Epstein-Barr (non contagious), also have had reactivated EBV for over a year. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 01, Manufacturer Unknown), for COVID-19 immunization. The following information was reported: POST VIRAL FATIGUE SYNDROME (non-serious), CHRONIC FATIGUE SYNDROME (non-serious), CONDITION AGGRAVATED (non-serious) all with onset 2021, outcome "recovering" and all described as "I have ME/CFS/ my condition has been exacerbated"; VACCINATION SITE PAIN (non-serious) with onset 2021, outcome "recovered with sequelae" (2021), described as "normal soreness around injection site for a few days". Therapeutic measures were not taken as a result of post viral fatigue syndrome, chronic fatigue syndrome, condition aggravated, vaccination site pain.  Additional information: Prior to vaccination the patient had not been diagnosed with COVID-19. The patient reported the events were not serious and did not require hospitalization. The patient reported that the vaccine itself was fine; only minor extra tiredness for a day or two after second dose and normal soreness around injection site for a few days. The patient was thrilled it went so well, but wanted to report she had ME/CFS, and while she was still glad she got the Pfizer mRNA vaccine, her condition had been exacerbated starting about a week after her second dose. She had much more inflammation and tiredness than usual, with some days really weak. Now about 4 months later, she thought it was starting to ease up but was not sure. Since vaccination the patient had not been tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
itching in her arm; 2 blisters below the injection site near her elbow.; This case was reported by a pharmacist via call center representative and described the occurrence of pruritus in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in March 2020).   On 20th July 2020, the patient received the 2nd dose of Shingrix. In July 2020, less than a week after receiving Shingrix, the patient experienced blister. On 20th July 2020, the patient experienced pruritus. On an unknown date, the outcome of the pruritus and blister were not recovered/not resolved.   It was unknown if the reporter considered the pruritus and blister to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and developed itching in her arm and 2 blisters below the injection site, near her elbow.   The events were ongoing. The reporter consented to follow up.
Narrative: COVID infection following COVID vaccine series 02/13, Moderna, dose #1 03/15, Moderna, dose#2 08/12 pt cc: chills fatigue, exposure: unknown 08/16 COVID swab, result: detected 08/16 SARS-COV-2 LINEAGE B.1.617.2 08/16 SARS-COV-2 CLADE 21A DELTA
Warmth, redness and swelling to her right deltoid 3/6/10 after immunization administered. Also swollen nymph nodes under both of her arms. Advised to do warm packs and take BENADRYL.
sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.            Treatment and concomitant medications were not provided by reporter.
This spontaneous report was received from a pharmacist referring to a 67 year old female patient. The patient's pertinent medical history and concurrent conditions were not reported. On 20-APR-2016, the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneously in the left arm (reported lot # L038926 with expiration date of 06-JAN-2017). The patient's concomitant medications were not reported. On 21-APR-2016, the patient developed a small orange raised spot at the injection site on the left arm, additionally the spot was itchy and no blisters or shingles were reported. On 22-APR-2016, the patient sought for attention on the pharmacy. Due to the event, the pharmacist advised the patient to use an unspecified cream for the itchiness. The pharmacist stated that the patient's husband was also vaccinated with ZOSTAVAX but no adverse effect was reported. Furthermore, no product quality issue was involved. At the time of the report, the outcome of injection site mass and pruritus were unknown. The relatedness between the adverse events and vaccination with ZOSTAVAX was not provided. Additional information has been requested.
Had the shot Got shingles/ Suspected vaccination failure; shingles / on left side of my head; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: This case was reported by patient himself/herself. The age at vaccination was not reported. The patient stated he/she had Shingles shot and got the shingle, still had them on left side of head. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming herpes zoster were unknown at the time of reporting. The follow-up would not possible as no contact details were available.
After 1 minute of receiving H1N1 vaccine c/o heaviness at shoulder, mild shortness of breath, and tiredness/weakening-(mild), /mild HA, felt better after 11 min of observation/rest. All vital signs normal.
No adverse event; Past lot that had also been expired that was administered to patient; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to patient) and NO ADVERSE EVENT (No adverse event) in a 46-year-old male patient who received mRNA-1273 (Spikevax) (batch no. O70H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    In 2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. In 2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to patient). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Past lot that had also been expired that was administered to patient).    Patient age was reported as 46 Year 4 Months.  No concomitant medication was provided.  NDC ID number was reported as 80777027398.   The lot number O70H21A was administered to patient between 08-Apr-2022 and 15-Dec-2022. It was reported that also another lot of vaccines lot number 065F21A was also expired and administered to patients.   Treatment medication was not provided by the reporter.
Patientis a 82 y.o. female with a history of COPD, RA, TIA who was admitted to first hospital 9/19-9/26/23 for COPD exacerbation (discharged on 3L NC), hospital stay complicated by possible Lyme's disease. She was discharged to SNF but family eloped  the pt within six hours due to reported suboptimal care. She represented to second hospital 9/26/2023 with persistent dyspnea and abdominal pain.  Found to have COPD exacerbation and COVID-19 +. Discharged to SNF 10/4/23 in stable condition.    1. COPD Exacerbation: Patient reports COPD normally stable on home regimen but very severe cough/dyspnea PTA. CXR 9/26/23 negative for focal consolidation. Completed doxycycline course. Continued steroid, pulmonary toilet, acapella, scheduled duonebs.  2. COVID Infection: Prior Vaccinations, (+) testing 9/27/23, completed 9 days of Decadron.  3. Acute on Chronic Hypoxic Respiratory Failure: discharged from first hospital to SNF on 9/26/23 on 3L NC. Required up to 4-5 L in p.m. on 10/4/2023 but with the goal O2 sat of greater than 88% patient was able to be weaned down to 3.5 L on discharge. 4. Indeterminate Lyme Serology: Patient with atypical rash on LEs and noted tick contact. Rash has resolved. Lyme serologies and skin biopsy at first hospital were inconclusive, ID at first hospital recommended empiric course of 10 days of doxycycline (completed).   5. Rheumatoid Arthritis: Held home methotrexate. Resume when ok with pts Rheumatology.  6. TIA: Continued home ASA/statin 7. Generalized Weakness: with deconditioning and reduced mobility POA. Patient reports she normally ambulates w/ walker, complains of significant weakness. Therapy recs for SNF.  8. Code Status: DNR-CCA